GALVANI, Elena
 Distribuzione geografica
Continente #
EU - Europa 358
NA - Nord America 331
AS - Asia 204
SA - Sud America 37
AF - Africa 11
OC - Oceania 1
Totale 942
Nazione #
US - Stati Uniti d'America 328
FI - Finlandia 108
CN - Cina 106
SG - Singapore 72
IE - Irlanda 62
SE - Svezia 55
IT - Italia 49
DE - Germania 37
BR - Brasile 31
TR - Turchia 17
NL - Olanda 16
UA - Ucraina 13
CI - Costa d'Avorio 8
BE - Belgio 5
EC - Ecuador 4
CA - Canada 3
IN - India 3
AT - Austria 2
FR - Francia 2
GB - Regno Unito 2
PL - Polonia 2
RU - Federazione Russa 2
AL - Albania 1
CY - Cipro 1
DZ - Algeria 1
ID - Indonesia 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
LU - Lussemburgo 1
MA - Marocco 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
TJ - Tagikistan 1
UY - Uruguay 1
VE - Venezuela 1
Totale 942
Città #
Chandler 62
Dublin 62
Singapore 36
Santa Clara 34
Parma 30
Jacksonville 27
Beijing 23
Ann Arbor 22
Dearborn 22
Izmir 17
Ashburn 16
Shanghai 16
Boardman 14
Nanjing 14
San Mateo 10
Munich 9
Abidjan 8
Bremen 8
New York 8
Princeton 8
Seattle 7
Hebei 6
The Dalles 6
Brussels 5
Kunming 5
Shenyang 5
São Paulo 5
Helsinki 4
Jinan 4
Düsseldorf 3
Jiaxing 3
Wilmington 3
Amsterdam 2
Changsha 2
Chongqing 2
Columbus 2
Council Bluffs 2
Des Moines 2
Gainesville 2
Grafing 2
Guangzhou 2
Hangzhou 2
Leawood 2
Mestre 2
Milan 2
Norwalk 2
Pune 2
Quito 2
Redwood City 2
Shaoxing 2
Tianjin 2
Toronto 2
Warsaw 2
Alvorada 1
Amman 1
Aracaju 1
Auckland 1
Augusta 1
Bauru 1
Bishkek 1
Boa Vista 1
Bologna 1
Borås 1
Bragança Paulista 1
Brasília 1
Cachoeiro de Itapemirim 1
Campinas 1
Campo Grande 1
Campo Verde 1
Caraguatatuba 1
Chengdu 1
Contagem 1
Cuenca 1
Dushanbe 1
Entre Rios de Minas 1
Fes 1
Fuzhou 1
Guarujá 1
Guarulhos 1
Hefei 1
Huizen 1
Islamabad 1
Jakarta 1
Jundiaí 1
Lissone 1
London 1
Los Angeles 1
Luxembourg 1
Machala 1
Modena 1
Monmouth Junction 1
Montegaldella 1
Montevideo 1
Moscow 1
Mountain View 1
Nairobi 1
Nanchang 1
Nicosia 1
Ningbo 1
Novo Hamburgo 1
Totale 591
Nome #
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 153
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 109
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 106
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 103
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 103
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 92
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 87
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 87
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling 80
null 31
Totale 951
Categoria #
all - tutte 3.467
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.467


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202014 0 0 0 0 0 0 0 0 0 0 5 9
2020/202146 1 4 2 1 7 0 3 0 12 4 12 0
2021/202246 2 0 0 7 1 2 5 5 3 5 6 10
2022/2023221 19 24 18 22 20 25 1 13 71 0 5 3
2023/202479 2 9 3 3 7 18 5 16 4 1 3 8
2024/2025234 9 12 14 20 39 47 10 9 42 17 15 0
Totale 951